Intrinsiqq

Xspray Pharma AB (XSPRAY.XSTO) Quality Score

XSPRAY.XSTO
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Cash Flow Multiple
0/100
-2.1x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
117.4%

Heavy dilution above 5%

Capital Structure
100/100
-kr 5M

Net cash position, no leverage concern

2022
kr 120M
kr 2M
2023
kr 166M
kr 37M
2024
kr 208M
kr 128M
2025
kr 154M
kr 148M
Return on Capital
0/100
-16.7%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Xspray Pharma AB (XSPRAY.XSTO) quality: score, margins and returns

Xspray Pharma AB (XSPRAY.XSTO) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -16.7% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Xspray Pharma AB (XSPRAY.XSTO) a high-quality business?+

Xspray Pharma AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -16.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Xspray Pharma AB's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from XSPRAY.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Xspray Pharma AB scores well and where it falls behind.

What is Xspray Pharma AB's return on invested capital (ROIC)?+

Xspray Pharma AB earns about -16.7% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to XSPRAY.XSTO's margins and growth on this scorecard to judge durability.

More on XSPRAY.XSTO: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Biotechnology

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing XSPRAY.XSTO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.